They achieved significant PLK1 gene silencing by more than 2-fold and improved cell targeting by 1.2 to over 4.5 times. In vivo, tumor uptake was average 3 times higher than controls and persisted up to 48 hours, suggesting an acceptable circulation half-life. This evidence concerns the gene PLK1 and neoplasm.